Alicaforsen is an antisense oligonucleotide targeted to down regulate the production of ICAM-1, a cell surface receptor which is involved in the process of inflammation. Alicaforsen selectively inhibits ICAM‑1 gene expression. Over-expression of ICAM‑1 occurs in a wide variety of inflammatory disorders, including ulcerative colitis (UC), pouchitis and tissues in the eye, gastrointestinal teact, lungs and skin. Alicaforsen is currently in development for the treatment of IBD. An enema formulation is currently in a pivotal Phase 3 study agreed with U.S., Canadian and European regulatory agencies in patients with active pouchitis. The study has completed enrollment of patients to approximately 40 trial centres across the U.S., Canada, Europe, and Israel, and is expected to report preliminary data in H1 2019. Under a rolling submission agreement with the FDA, Atlantic Healthcare has filed the nonclinical data package of its New Drug Application (NDA) for alicaforsen to treat pouchitis with the regulator. Alicaforsen has also been granted FDA Fast-Track designation, plus U.S. and European Orphan Drug designations for this indication.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02525523
Pouchitis: Alicaforsen enema, 240mg once daily for 6 weeks
Route of Administration:
Rectal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11305914
Alicaforsen demonstrated hyperbolic, mixed-type inhibition of chromogenic substrate cleavage by factor IXa (K(I) = 88 nM). Equilibrium binding studies with fluorescein-labeled Alicaforsen demonstrated a similar affinity (K(D) = 92 nM) for the PS ODN-factor IX interaction.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/09/641
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
||
|
FDA ORPHAN DRUG |
260808
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
J8435V445B
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY | |||
|
C169771
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY | |||
|
DTXSID701030532
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL2108326
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY | |||
|
m1507
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
8135
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY | |||
|
DB06224
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY | |||
|
16197725
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL2108895
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY | |||
|
SUB130333
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY | |||
|
185229-68-9
Created by
admin on Sat Dec 16 17:40:37 GMT 2023 , Edited by admin on Sat Dec 16 17:40:37 GMT 2023
|
PRIMARY |
Sugar | Site Range | Site Count |
---|---|---|
Deoxyribose (DNA) | 1_1-1_20 | 20 / 20 |
Linkage | Site Range | Site Count |
---|---|---|
Phosporothioate | 1_2-1_20 | 19 / 19 |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)